title: The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.
abstract: BACKGROUND
  Oral triptans have dominated the prescription market for acute treatment of migraine for nearly 25 years. Today, patients often express dissatisfaction with prescribed acute treatment in part because they do not have confidence that the therapy will provide consistent efficacy over time. Major limitations to sustained successful use of oral triptans are their relatively slow onset of meaningful clinical benefit and variable absorption/efficacy due to impaired gastrointestinal function during migraine. AVP-825, a new intranasal delivery system for sumatriptan , may be an effective alternative to oral triptans.
  
  
  METHODS
  This article reviews AVP-825, which deposits low-dose sumatriptan powder deep into the vascular mucosa of the posterior nose, allowing rapid absorption of drug into the systemic circulation. Studies suggest that AVP-825 is a highly effective, well-tolerated acute treatment for episodic migraine.
  
  
  CONCLUSIONS
  Oral triptans are limited in providing effective patient-centered outcomes to migraine patients. Failed or suboptimal abortive treatment of migraine is a major driver of migraine chronification and increases in healthcare costs. AVP-825 is an easy to use, novel, breath-powered intranasal delivery system that provides early onset of efficacy with low systemic drug exposure and few triptan-associated adverse events. AVP-825 will be a welcomed therapeutic tool for the acute treatment of migraine.
authors.affiliation: Headache Care Center , 3805 S, Kansas Expressway, Springfield, MO 65807 , USA +1 417 890 7888 ; rcady@banyangroupinc.com.
authors.forename: Roger
authors.initials: R
authors.lastname: Cady
mesh_terms: D000281:Administration, Intranasal; D015507:Drugs, Investigational; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan
keywords: AVP-825; acute migraine treatment; intranasal drug delivery; sumatriptan